AERI - Aerie Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
43.99
+1.16 (+2.71%)
At close: 4:00PM EST

43.99 0.00 (0.00%)
After hours: 6:04PM EST

Stock chart is not supported by your current browser
Previous Close42.83
Open42.85
Bid30.25 x 800
Ask54.50 x 900
Day's Range42.30 - 45.00
52 Week Range32.18 - 74.75
Volume647,224
Avg. Volume582,709
Market Cap2B
Beta (3Y Monthly)0.58
PE Ratio (TTM)N/A
EPS (TTM)-6.07
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est83.10
Trade prices are not sourced from all markets
  • Aerie's (AERI) Eye Care Candidate to Enter Clinical Studies
    Zacks9 hours ago

    Aerie's (AERI) Eye Care Candidate to Enter Clinical Studies

    Aerie's (AERI) Investigational New Drug Application for AR-1105 for the treatment of macular edema due to retinal vein occlusion is accepted by the FDA. The candidate will now enter clinical studies.

  • A Spotlight On Aerie Pharmaceuticals, Inc.’s (NASDAQ:AERI) Fundamentals
    Simply Wall St.yesterday

    A Spotlight On Aerie Pharmaceuticals, Inc.’s (NASDAQ:AERI) Fundamentals

    I've been keeping an eye on Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) because I'm attracted to its fundamentals. Looking at the company as a whole, as a potential stock investment, I believe Read More...

  • Markityesterday

    See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.

    # Aerie Pharmaceuticals Inc ### NASDAQ NMS:AERI View full report here! ## Summary * Bearish sentiment is moderate and increasing ## Bearish sentiment Short interest | Negative Short interest is moderately high for AERI with between 10 and 15% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on December 19. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. The net inflows of $2.17 billion over the last one-month into ETFs that hold AERI are not among the highest of the last year and have been slowing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Business Wireyesterday

    Aerie Pharmaceuticals Announces Acceptance of Its Investigational New Drug Application for AR-1105 (Dexamethasone Intravitreal Implant)

    Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye today announced that the U.S. Food and Drug Administration (FDA) has reviewed the Investigational New Drug Application (IND) for AR-1105 (dexamethasone intravitreal implant) and it is now in effect, allowing Aerie to initiate human studies in the treatment of macular edema due to retinal vein occlusion (RVO). The IND was submitted in December 2018.

  • How to spot risky biotech companies and six to avoid now
    MarketWatch2 days ago

    How to spot risky biotech companies and six to avoid now

    With biotechnology exchange traded funds down as much as 20% from their highs last year, it’s now tempting to shop for bargains. It had cash of $11 million and annualized losses of $94 million, for a very troubling risk ratio of 0.1.

  • Markit9 days ago

    See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.

    # Aerie Pharmaceuticals Inc ### NASDAQ NMS:AERI View full report here! ## Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate and increasing ## Bearish sentiment Short interest | Negative Short interest is moderately high for AERI with between 10 and 15% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on December 19. ## Money flow ETF/Index ownership | Positive ETF activity is positive. Over the last month, growth of ETFs holding AERI is favorable, with net inflows of $5.38 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Aerie's Rhopressa Succeeds in Study on Japanese Patients
    Zacks11 days ago

    Aerie's Rhopressa Succeeds in Study on Japanese Patients

    Aerie (AERI) announces encouraging top-line results from its pilot phase II study of netarsudil ophthalmic solution in a Japan.

  • Business Wire14 days ago

    Aerie Pharmaceuticals Announces Positive Topline Results of Netarsudil Ophthalmic Solution in Pilot Phase 2 Study Supporting Clinical Development in Japan

    Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye today announced the topline results of its pilot Phase 2 study of netarsudil ophthalmic solution in a Japanese-American population. The study was designed in accordance with the requirements of Japan’s PMDA (Pharmaceuticals and Medical Devices Agency) to support the potential regulatory submission of netarsudil ophthalmic solution in Japan.

  • Business Wire16 days ago

    Aerie Pharmaceuticals Announces Appointment of Ami Bavishi as Director, Investor Relations and Vincent Santucci, Pharm.D., as Director, Scientific Market Access

    Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, today announced the appointment of Ami Bavishi as Director, Investor Relations, reporting to Richard Rubino, Aerie’s Chief Financial Officer. Ms. Bavishi will drive all of Aerie’s investor relations activities, and joins Aerie from Burns McClellan, a public relations and investor relations firm with which Aerie will maintain an ongoing relationship.

  • Markitlast month

    See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.

    # Aerie Pharmaceuticals Inc ### NASDAQ NMS:AERI Score: Neutral (42) 6 days at current score. Upgraded from Negative on December 8th 2018 View full report here! ## Summary * This company ranked positively in all 3 IHS Markit categories but was neutral compared to the Healthcare sector * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate and declining * Economic output in this company's sector is expanding ## Bearish sentiment Short interest | Positive Short interest is moderate for AERI with between 5 and 10% of shares outstanding currently on loan. However, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on November 27. ## Money flow ETF/Index ownership | Positive ETF activity is positive. Over the last month, ETFs holding AERI are favorable, with net inflows of $1.78 billion. Additionally, the rate of inflows is increasing. ## Economic sentiment PMI by IHS Markit | Positive According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Benzingalast month

    Aerie Division's Prospects Have Analysts Bullish On American Eagle

    American Eagle Outfitters (NYSE: AEO) shares are moving higher despite reporting a third-quarter sales miss Wednesday. The analyst highlighted Aerie as a bright spot for the company, with comps accelerating sequentially to positive 32 percent in the quarter. B Riley FBR analyst Susan Anderson also remains bullish on the company despite the sales miss, reiterating a Buy rating and $29 price target.

  • Hedge Funds Are Selling Aerie Pharmaceuticals Inc (AERI)
    Insider Monkeylast month

    Hedge Funds Are Selling Aerie Pharmaceuticals Inc (AERI)

    Out of thousands of stocks that are currently traded on the market, it is difficult to determine those that can really generate strong returns. Hedge funds and institutional investors spend millions of dollars on analysts with MBAs and PhDs, who are industry experts and well connected to other industry and media insiders on top of that. Individual investors can piggyback […]

  • Should You Get Rid of Aerie Pharmaceuticals (AERI) Now?
    Zackslast month

    Should You Get Rid of Aerie Pharmaceuticals (AERI) Now?

    Aerie Pharmaceuticals (AERI) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.

  • GlobeNewswirelast month

    Investor Expectations to Drive Momentum within Mirati Therapeutics, comScore, Nuance Communications, Carnival, Aerie Pharmaceuticals, and TrueCar — Discovering Underlying Factors of Influence

    NEW YORK, Dec. 04, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.

    Aerie Pharmaceuticals Inc NASDAQ NMS:AERI

  • See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.

    Short interest is moderately high for AERI with between 10 and 15% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.

  • Mariko Gordon's Top 5 New Buys
    GuruFocus.com2 months ago

    Mariko Gordon's Top 5 New Buys

    Daruma Capital Management's Mariko Gordon (Trades, Portfolio) released her third-quarter portfolio last week, listing seven new holdings. Warning! GuruFocus has detected 6 Warning Signs with PRAA. Gordon's New York-based firm manages a concentrated portfolio of small and mid-cap companies.

  • Aerie Pharmaceuticals (AERI): Moving Average Crossover Alert
    Zacks2 months ago

    Aerie Pharmaceuticals (AERI): Moving Average Crossover Alert

    Aerie Pharmaceuticals, Inc. (AERI) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front

  • See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.

    Aerie Pharmaceuticals Inc NASDAQ NMS:AERI

  • Aerie (AERI) Q3 Earnings Miss, Rhopressa Gains Traction
    Zacks2 months ago

    Aerie (AERI) Q3 Earnings Miss, Rhopressa Gains Traction

    Aerie's (AERI) Q3 loss is wider than expected on account of higher expenses. Nevertheless, Rhopressa's sales beat estimates as demand picks up.

  • Business Wire2 months ago

    Aerie Pharmaceuticals to Present at the Stifel 2018 Healthcare Conference

    Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, today announced that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will present in a fireside discussion at the Stifel 2018 Healthcare Conference on Tuesday, November 13, 2018 at 10:15 a.m. Eastern Time in New York, NY. Dr. Anido will provide an Aerie overview and business update.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of AERI earnings conference call or presentation 6-Nov-18 10:00pm GMT

    Q3 2018 Aerie Pharmaceuticals Inc Earnings Call

  • Aerie Pharmaceuticals (AERI) Reports Q3 Loss, Tops Revenue Estimates
    Zacks2 months ago

    Aerie Pharmaceuticals (AERI) Reports Q3 Loss, Tops Revenue Estimates

    Aerie (AERI) delivered earnings and revenue surprises of -30.08% and 29.79%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press2 months ago

    Aerie: 3Q Earnings Snapshot

    The North Carolina, North Carolina-based company said it had a loss of $1.96 per share. Losses, adjusted for non-recurring costs, were $1.73 per share. The results did not meet Wall Street expectations. ...

  • Business Wire2 months ago

    Aerie Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update

    Conference Call and Webcast Today, November 6th, at 5:00 p.m. ET